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Background: The brain-derived neurotrophic factor (BDNF) protein has been shown to
have a prominent role in neuron survival, growth, and function in experimental models,
and the BDNF Val66Met polymorphism which regulates its expression has been linked
to resilience toward the effects of aging on cognition. Cognitively stimulating activity is
linked to both increased levels of BDNF in the brain, and protection against age-related
cognitive decline. The aim of this study was to investigate the associations between
serum BDNF levels, the BDNF Val66Met genotype, and components of cognitive reserve
in early and mid-life, measured with the Lifetime of Experiences Questionnaire (LEQ).
Methods: Serum BDNF levels were measured cross-sectionally in 156 participants from
the Tasmanian Healthy Brain Project (THBP) cohort, a study examining the potential
benefits of older adults engaging in a university-level education intervention. Multiple
linear regression was used to estimate serum BDNF’s association with age, education,
gender, BDNF Val66Met genotype, later-life university-level study, and cognitively
stimulating activities measured by the LEQ.
Results: Serum BDNF in older adults was associated with early life education and
training, increasing 0.007 log(pg/ml) [95%CI 0.001, 0.012] per unit on the LEQ subscale.
Conversely, education and training in mid-life were associated with a −0.007 log(pg/ml)
[−0.012, −0.001] decrease per unit on the LEQ subscale. Serum BDNF decreased with
age (−0.008 log(pg/ml) [−0.015, −0.001] per year), and male gender (−0.109 log(pg/ml)
[−0.203, −0.015]), but mean differences between the BDNF Val66Met polymorphisms
were not significant (p = 0.066). All effect sizes were small, with mid-life education and
training having the largest effect size (η2p = 0.044).
Conclusion: Education in both early and mid-life explained small but significant amounts
of variance in serum BDNF levels, more than age or gender. These effects were opposed
and independent, suggesting that education at different stages of life may be associated
with different cognitive and neural demands. Education at different stages of life may be
important covariates when estimating associations between other exposures and serum
BDNF.
Keywords: education, serum, polymorphism, cognitive reserve, brain derived neurotrophic factor, Alzheimer’s
disease, biomarkers
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INTRODUCTION
A of evidence suggests an individual’s risk of developing
dementia is influenced by genetic and environmental factors,
and their interactions (Lourida et al., 2019). One environmental
factor which has been strongly linked to dementia risk is
early life education, with lower levels of education conferring
an increased risk of dementia (Livingston et al., 2020)
and cognitive stimulation suggested to improve resilience to
dementia. This evidence, in combination with post-mortem
studies demonstrating some people without clinical symptoms of
dementia prior to death, exhibit high levels of dementia-related
pathology in the brain (Roe et al., 2007; Price et al., 2009), has led
to the proposition of a theoretical construct known as ‘‘cognitive
reserve.’’ The cognitive reserve can thus be conceptualized as an
individual’s resilience to neuropathological insult.
Although the mechanisms underlying cognitive reserve are
unclear, the links between resilience to brain pathology and
cognitive stimulation (Stern, 2002) suggest a dependence on
synaptic plasticity. The protein, brain-derived neurotrophic
factor (BDNF) has been implicated in the beneficial effects of
cognitively stimulating activities as it is a regulator of synaptic
transmission, inducing long-term changes in excitability and
synaptic plasticity in the adult brain (Miranda et al., 2019).
Cognitive stimulation, which increases BDNF levels in the
brain in BDNF+/− mice compared with wildtype (Novkovic
et al., 2015), has also been shown to play an important
role in learning and memory (Mather, 2020). Higher serum
BDNF levels have been suggested to protect against dementia
occurrence (Weinstein et al., 2014), therefore they may represent
an important mediator of the beneficial effects of cognitively
stimulating activities on cognitive reserve and dementia risk.
The BDNF gene has a common single nucleotide
polymorphism causing a valine to methionine amino acid
substitution at residue 66 (Val66Met) and Met allele carriers
have been shown to exhibit reduced synaptic activity and greater
cognitive decline compared to Val/Val homozygotes (Miyajima
et al., 2008; Lim et al., 2013). In healthy adults aged 71.36 (±7.15)
years with evidence of amyloid pathology, Met carriers showed
significant declines in episodic memory, executive function, and
language compared to their Val/Val homozygote counterparts
(Lim et al., 2013). However, other studies have shown conflicting
results and meta-analyses have failed to establish an association
with cognition (Mandelman and Grigorenko, 2012). Therefore,
the effect of the BDNF Val66Met polymorphism on healthy
cognitive ability requires further investigation, particularly
the relationship between the BDNF Val66Met polymorphism,
cognitive stimulation, and cognitive reserve.
The expression of BDNF is tightly regulated and its synthesis
and secretion by neurons is affected by multiple factors including
stress, exercise, and learning (Ickes et al., 2000; Mattson et al.,
2004). Furthermore, BDNF released in the brain, can cross the
blood-brain barrier (Pan et al., 1998) and is present in peripheral
circulating blood in both plasma and platelets (Radka et al.,
1996). Serum BDNF levels are more than 100 times higher
than plasma BDNF levels. This is due to the degranulation of
platelets during the clotting process, which contain high amounts
of protein (Rosenfeld et al., 1995; Radka et al., 1996; Fujimura
et al., 2002). In peripheral blood, platelets circulate for 11 days,
whereas the BDNF protein circulates in plasma for less than 1 h.
Thus, serum BDNF levels may represent a long-term measure
of brain BDNF levels. In contrast, plasma BDNF concentrations
may vary with events in the hours leading up to blood collection
(Lommatzsch et al., 2005).
A study in rats indicates that BDNF levels in both plasma
and serum correlate with brain levels of the protein (Karege
et al., 2002), and several non-human studies have described
circulating levels of BDNF as a proxy for expression in the
brain (Sartorius et al., 2009; Klein et al., 2011). Human studies
of BDNF levels in serum and the brain have demonstrated
levels decrease with age and that lower serum BDNF levels are
associated with lower spatial memory performance (Erickson
et al., 2010). Furthermore, a community-based prospective study
of 2,131 participants, followed for up to 10 years by Weinstein
et al. (2014), found that higher serum BDNF levels were
associated with a reduction in risk of dementia and Alzheimer’s
disease (AD). However, studies examining the effect of the BDNF
Val66Met polymorphism on brain and serum BDNF levels
demonstrate mixed results, with Met carriers reported to have
both lower (Ozan et al., 2010), higher (Lang et al., 2009; Minelli
et al., 2011) and similar (Yu et al., 2008) levels compared to Val
homozygotes. SerumBDNF levels also display heterogeneity with
respect to gender (Lang et al., 2009; Ozan et al., 2010; Shimada
et al., 2014), therefore the relationship between circulating BDNF
levels, gender, BDNF genotype, and age-related cognitive decline
is unclear.
The TasmanianHealthy Brain Project (THBP) is a prospective
longitudinal study of cognitively healthy people aged 50 years
or more with a self-nominated intervention group undertaking
later life university-level education (Summers et al., 2013). The
overall aim of the project is to investigate the potential of later-life
university-level education to increase cognitive performance,
enhance cognitive reserve, and subsequently reduce age-
related cognitive decline. Previously, data from this study has
demonstrated that the BDNFVal66Met polymorphism positively
moderates the relationship between cognitive reserve and
executive function in Val homozygotes, but not in Met carriers
(Ward et al., 2017). It has also shown that later-life university-
level education leads to a significant increase in cognitive reserve
(Lenehan et al., 2016) and language processing capacity (Thow
et al., 2018). Additionally, the amount of education undertaken
benefited language processing performance in a dose-dependent
manner in BDNF Met carriers, but not Val homozygotes (Ward
et al., 2019). Using cross-sectional data from the THBP, the
current exploratory study aimed to determine whether BDNF
levels in serum were related to the BDNF Val66Met genotype.
This study was conducted in non-impaired cognitively healthy
adults, which is particularly important given the pre-clinical
prodrome in cognitive decline, and the necessity to conduct
preventative research as early as possible along the disease course.
Furthermore, we aimed to determine whether serum BDNF
levels were related to the participants’ cognitive reserve, using
subscales of the Lifetime of Experiences Questionnaire (LEQ) to
measure education and training, career attainment, and other
Frontiers in Aging Neuroscience | www.frontiersin.org 2 August 2021 | Volume 13 | Article 725914
Collins et al. Age, Education and Serum BDNF
cognitively stimulating activities in young adulthood and mid-
life. Finally, we were interested to investigate how later-life
university study, the hallmark intervention of the THBP, related
to serum BDNF levels in healthy older adults.
MATERIALS AND METHODS
Cognitive Reserve
The THBP is an ongoing longitudinal study that commenced
in 2011. For the first 4 years, participants attend annual
clinical assessments, followed by biennial, full details have been
published previously (Summers et al., 2013; Ward et al., 2014).
Assessments are conducted in-person at a clinical research
facility in Hobart, Tasmania, by a trained neuropsychologist. At
each assessment, participants complete a medical health status
questionnaire assessing health, medical conditions, prescription
medication use, and drug and alcohol use for the preceding
12/24 months. This questionnaire was designed specifically for
the THBP, collecting demographic information such as age (in
years), gender (options either ‘‘male’’ or ‘‘female’’), handedness,
height (in cm), weight (in kg), marital status, education (in years)
and occupational history.
To account for THBP participant’s engagement with
cognitively stimulating activities at different stages across
the lifespan, the cognitive reserve was treated as individual
subscales from; university study (participation in later-life
education as part of the THBP), premorbid intelligence
quotient [Weschler Test of Adult Reading (WTAR), Full-Scale
IQ (FSIQ)], and lifetime cognitive stimulation [Lifetime
Experiences Questionnaire (LEQ)]. Both the WTAR and
LEQ were completed at baseline, whilst participation in the
THBP educational intervention was calculated retrospectively.
Developed by Valenzuela and & Sachdev (2007), the LEQ
assesses educational, occupational, and cognitive lifestyle
activities at different stages through life. We used the LEQ’s
early life and midlife indicators of cognitive reserve; young
adult specific, young adult nonspecific, midlife specific, and
midlife bonus. A score on the LEQ young adulthood specific of
15.7 could represent the completion of approximately 5 years
of secondary school and a university undergraduate degree,
whilst a score of 10.1 for midlife bonus could represent the
completion of a Ph.D. We did not assess the later-life subscales
of the LEQ because few participants were old enough to
complete this section. WTAR-FSIQ provides a stable and reliable
estimate of premorbid intellectual capacity (The Psychological
Corporation, 2001). For the WTAR-FSIQ, participants were
given the word list at neuropsychological assessment and asked
to articulate 50 words with an atypical grapheme to phoneme
translation (such as ‘‘ballet’’ or ‘‘aisle’’). Finally, a participant’s
engagement with the THBP university-level education was
included, measured as years of full-time study equivalent at
university completed as part of the THBP intervention.
Genotyping
Participants of the THBPwere genotyped as previously described
in 2014 (Stuart et al., 2014). DNA samples were extracted
from saliva and collected with Oragene DNA self-collection
kits (Genotek, ON, Canada, 2012). BDNF genotypes were
determined through one-step amplified refractory mutation
system PCR31 and subsequent gel electrophoresis. Genetic
polymorphisms were determined by following previously
described methods for BDNF (Sheikh et al., 2010). PCR
amplifications were undertaken in a 12-µl reaction volume
that contained ∼50 ng of genomic DNA. PCR amplicons were
resolved on 2% agarose gel.
Blood Collection
Blood was collected, processed, and stored according to
published guidelines for AD research (O’Bryant et al., 2015).
Briefly, non-fasting blood was collected by venepuncture with
aseptic technique using a 21-gauge (G) butterfly needle into
BD VacutainerTM SSTTM II Advance tubes (Cat no. 367958).
For the preparation of serum, blood was clotted in a vertical
position at room temperature for 30 min prior to centrifugation
at 1,500 g for 10 min at 4◦C. Serum was then aliquoted
into 10 polypropylene, screw-top cryostorage tubes to prevent
multiple freeze-thaw cycles, and stored at−80◦C. The time from
venepuncture to the storage of serum and plasma samples at
−80◦C was under 2 h.
BDNF
BDNF measurements in serum samples were performed
using the BDNF Discovery Kit single-molecule array assay
(Simoar) from Quanterix (Cat no. 102039). Calibrators,
participant samples, and two quality control samples per
plate were measured in duplicate using a 2-step assay on a
Simoa SR-X platform (Quanterix) according to manufactures
protocols. Serum samples were diluted 1/1,000. The intra-assay
concentration coefficient of variation was calculated for the
duplicates of each participant sample and if they were more than
20% the sample was remeasured as per DeWolf et al. (2020). The
intra-assay coefficient of variation for included sample measures
was 7.2%. The median values for bi-participant replicates were
then calculated and if the absolute difference between a replicate
and the median value exceeded 10% of the median, the replicate
was treated as an outlier and deleted from the statistical analysis.
The mean of each biomarker concentration was then calculated
for each participant sample.
Participants
A total of 566 THBP participants were progressively recruited
from 2011 to 2014 through general advertising including
newspaper, website, radio, television, and public lectures.
Participants were eligible if there was no history of prior
conditions known to be associated with an impaired neurological
function such as dementia; multiple sclerosis; prior head
injury requiring hospitalization; epilepsy; cerebrovascular
complications including stroke, aneurysm, transient ischaemic
attacks; poorly controlled diabetes; poorly controlled
hypertension or hypotension; other neurological disorders,
e.g., cerebral palsy or spina bifida; chronic obstructive
pulmonary disease; heart disease; partial or total blindness;
deafness; current psychiatric diagnosis (for further details
please see Summers et al., 2013). On entry into the THBP,
and reflecting a lengthy ‘‘real-world’’ intervention, participants
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opted (non-random assignment) into university-level education
(439 later-life university study, 78%) or no further education
(127 control, 22%). Participation in the THBP is ongoing and
participants are still completing university-level subjects as
part of the educational intervention (Hill et al., 2020). To date,
156 participants (27.5% over 9 years) have withdrawn, with
dropout proportions similar to group proportions (44 control,
28%; 112 intervention, 72%). Of the participants who withdrew,
the majority cited factors unrelated to the study as their reason of
withdrawal: 22% relocated, 13% unable to recontact, 9% too busy,
10% medical diagnosis, 6% deceased, 3% work commitments,
2% family issues, 28% provided no reason; and 7% reported the
assessments too stressful. All THBP participants were invited
to take part in this biomarker sub-study and blood samples
were collected from 174 (39 control, 22%; 135 intervention,
78%) participants in 2018. All participants were asked to avoid
exercise in the 24 h prior to their blood collection. This project
received ethical approval from the University of Tasmania
Health and Medical HREC (H0018265 and H0016317) and
was carried out in accordance with the Declaration of Helsinki.
All participants signed written informed consent before
participation.
Statistics
In order to determine which variables (including potential
confounders) were associated with serum BDNF, a multiple
linear regression model (Model 1) was fitted which included
all LEQ young adulthood and mid-life subscales, age in
years, self-reported gender, WTAR-FSIQ, BDNF Val66Met
polymorphism, and years of full-time equivalent university study
as part of the THBP. Terms in Model 1 with p < 0.10 were
included in a final model (Model 2) for inference (Chowdhury
and Turin, 2020; age was retained as a covariate on the basis of
strong previous evidence demonstrating a relationship between
age and serum BDNF levels e.g., Erickson et al., 2010; Shimada
et al., 2014). Variables in Model 2 with p< 0.05 were considered
significant. F-statistics were computed using type 2 sums of
squares. Serum BDNF (pg/ml) was loge-transformed to improve
the normality of residuals following inspection of Q-Q plots.
We have reported partial eta-squared as a standardized measure
of effect size since it is easily interpreted as the proportion of
variance explained by a single variable in a model with many
variables. All analysis was conducted in the R environment for
statistical computing (R Core Team, 2013). Reproducible R code
is provided at https://github.com/ABindoff/bdnf_cr.
RESULTS
Descriptive Statistics
A total of 174 participants provided blood samples for analysis.
After excluding outliers based on serum BDNF measurements
(n = 18), samples from 156 participants were used in the
analysis. Participants had an average age of 69.8 years (SD 6.2,
range 58–84) and 14.1 years (SD 2.4) of early life education
(Table 1). A total of 107 (69%) participants were female. Of the
145 participants with genotypic data (11 missing), 89 were BDNF
Val66Met− (57.1%) while 56 were BDNF Val66Met+ (35.9%).
Mean serum levels of BDNF were 20,600 pg/ml (SD 5760;
Table 1). Serum BDNF levels were higher in females [21,100
(SD = 5,500) pg/ml] compared with males [19,700 (SD = 6,250)
pg/ml].
Model Selection
Variables with p-values <0.10 were BDNF Val66Met, gender,
and the two LEQ subscales of education and training in
young adulthood and mid-life (Table 2). These variables, and
age, were retained in the reported multiple linear regression
model. Years of university study with the THBP, LEQ young
adulthood general, midlife specific—occupation, midlife general
and WTAR FSIQ were not significantly associated with serum
BDNF.
Inferential Statistics
Age was significantly associated with a −0.008 [95%CI −0.015,
−0.001] decrease in log(pg/ml) serum BDNF concentrations
per year of age (p = 0.032; η2p = 0.036; Table 2). Males
had −0.109 [−0.203, −0.015] lower log(pg/ml) serum BDNF
concentrations than females (p = 0.023; η2p = 0.022). Figure 1A
illustrates the estimated marginal mean age trends stratified by
gender. Participants who carried at least one Met allele had
0.08 [−0.009, 0.169] log(pg/ml) higher serum BDNF than Val
homozygotes, but this difference was not significant (p = 0.077;
η2p = 0.025).
Education and training subscales were significantly associated
with serum BDNF concentrations, but the direction of these
associations differed for young adulthood and mid-life subscales
(Figure 1B). Education and training in young adulthood
(LEQ young adulthood specific—education) was associated with
a 0.007 [.001, 0.012] increase in log(pg/ml) serum BDNF
per unit on the subscale, while education and training in
mid-life (LEQ midlife bonus—education) was associated with a
−0.007 [−0.012, −0.001] decrease in log(pg/ml) serum BDNF
(p = 0.022 and p = 0.013 for young adulthood and mid-life,
respectively). Although significant, both effect sizes were small
(η2p = 0.044 for mid-life and η
2
p = 0.037 for young adulthood,
Figure 1). Model 2 explained 11.5% of variance (adjusted R2).
Since a correlation between education and training at
different life stages would result in biased estimates, we fitted
covariate-adjusted models for young adulthood and mid-life
education and training variables separately and obtained the
same coefficients and confidence intervals (to 3 decimal places)
as the model with both variables included. We observed
no significant correlation between education and training in
young adulthood (LEQ young adulthood specific—education) vs.
mid-life (LEQ midlife bonus—education, Pearson’s r = −0.03,
p = 0.744).
DISCUSSION
We present a cross-sectional investigation of serum BDNF levels
in healthy, older Australian adult participants of the THBP,
a longitudinal study of the effects of a complex cognitive
stimulation in the form of university-level education. Our
findings indicate increasing age, lower cognitive stimulation in
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TABLE 1 | Characteristics of all included THBP participants (n = 156).
Female (N = 107) Male (N = 49) Overall (N = 156)
BDNF in serum log(pg/ml)
Mean (SD) 21,100 (5500) 19,700 (6250) 20,600 (5760)
Median [Min, Max] 20,300 [9820, 41700] 18,500 [7810, 35000] 20,000 [7810, 41700]
Age (years)
Mean (SD) 69.6 (6.39) 70.1 (5.90) 69.8 (6.22)
Median [Min, Max] 70.0 [58.0, 84.0] 71.0 [58.0, 83.0] 70.5 [58.0, 84.0]
BDNF Val66Met genotype
met- 61.0 (57.0%) 28.0 (57.1%) 89.0 (57.1%)
met+ 37.0 (34.6%) 19.0 (38.8%) 56.0 (35.9%)
Missing 9.00 (8.4%) 2.00 (4.1%) 11.0 (7.1%)
Education (early life)
Mean (SD) 13.8 (2.42) 14.7 (2.33) 14.1 (2.42)
Median [Min, Max] 13.0 [9.00, 21.0] 15.0 [10.0, 19.0] 14.0 [9.00, 21.0]
FTE Years of university study (THBP intervention)
Mean (SD) 1.26 (1.39) 1.00 (1.18) 1.18 (1.33)
Median [Min, Max] 0.875 [0, 7.50] 0.500 [0, 4.38] 0.750 [0, 7.50]
LEQ young adulthood specific (education)
Mean (SD) 14.2 (7.31) 18.8 (7.68) 15.7 (7.70)
Median [Min, Max] 12.6 [3.15, 44.1] 18.9 [4.20, 35.7] 15.5 [3.15, 44.1]
LEQ young adulthood general
Mean (SD) 24.2 (5.74) 25.6 (5.35) 24.6 (5.64)
Median [Min, Max] 24.0 [11.0, 38.0] 26.0 [15.0, 34.0] 24.0 [11.0, 38.0]
LEQ midlife specific (occupation)
Mean (SD) 18.7 (4.72) 20.9 (3.30) 19.4 (4.43)
Median [Min, Max] 19.0 [2.50, 25.5] 21.0 [14.0, 25.5] 19.5 [2.50, 25.5]
LEQ midlife general
Mean (SD) 24.8 (4.89) 25.0 (4.73) 24.9 (4.83)
Median [Min, Max] 25.0 [13.0, 36.0] 26.0 [11.0, 33.0] 25.0 [11.0, 36.0]
LEQ midlife bonus (education)
Mean (SD) 9.79 (7.75) 9.10 (9.11) 9.57 (8.18)
Median [Min, Max] 8.40 [0, 32.6] 8.40 [0, 46.2] 8.40 [0, 46.2]
Missing 1.00 (0.9%) 0 (0%) 1.00 (0.6%)
LEQ later-life specific (occupation)
Mean (SD) 7.95 (4.69) 6.72 (1.35) 7.56 (3.96)
Median [Min, Max] 7.38 [4.00, 33.0] 6.50 [4.25, 8.75] 7.00 [4.00, 33.0]
Missing 71.0 (66.4%) 32.0 (65.3%) 103 (66.0%)
LEQ later-life general
Mean (SD) 23.9 (6.15) 21.0 (3.81) 23.0 (5.64)
Median [Min, Max] 24.5 [1.20, 38.0] 21.0 [16.0, 30.0] 23.0 [1.20, 38.0]
Missing 71.0 (66.4%) 32.0 (65.3%) 103 (66.0%)
LEQ later-life bonus (education)
Mean (SD) 1.53 (4.09) 2.61 (6.10) 1.88 (4.80)
Median [Min, Max] 0 [0, 23.0] 1.26 [0, 26.0] 0.550 [0, 26.0]
Missing 72.0 (67.3%) 32.0 (65.3%) 104 (66.7%)
WTAR FSIQ
Mean (SD) 113 (5.30) 112 (6.28) 113 (5.61)
Median [Min, Max] 114 [92.0, 122.0] 114 [83.0, 118.0] 114 [83.0, 122.0]
Means, medians, and standard deviations (SD) presented for continuous measures. Otherwise, sample size and missing (% of total) values reported. BDNF, brain-derived neurotrophic
factor, FTE, full-time equivalent; LEQ, lifetime experience questionnaire; SD, standard deviation; THBP, Tasmanian Healthy Brain Project; WTAR FSIQ, Weschler Test of Adult Reading
Full-Scale Intelligence Quotient.
young adulthood, and higher cognitive stimulation in mid-life
are associated with lower serum BDNF levels in healthy adults
aged between 50 and 76 years. Whilst we may have predicted
the positive association with early-life cognitive stimulation
(Weinstein et al., 2014; Novkovic et al., 2015) and reduction
in serum BDNF with aging (Erickson et al., 2010; Shimada
et al., 2014), the lower concentration of serum BDNF in people
with higher cognitive stimulation in mid-life was surprising. A
number of explanations seem possible, and it may be useful to
challenge some of the assumptions we have about BDNF and its
presence in the periphery.
It is broadly accepted that higher BDNF level in the blood is
a beneficial state, reflecting greater brain levels (Rasmussen et al.,
2009). This aligns with lower serum BDNF levels throughout
aging, as BDNF levels are associated with the decline in
neural processing and function with increasing age (Shimada
et al., 2014). Previous literature has indicated that lower serum
BDNF levels were related to the development of mild cognitive
impairment (Shimada et al., 2014), AD (Ng et al., 2019) and
higher brain BDNF levels are related to slower rates of cognitive
decline (Buchman et al., 2016). However, Laske et al. (2006) have
shown that people in the early stages of probable AD had higher
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TABLE 2 | Linear regression coefficients with 95% confidence intervals for the associations between age, BDNF Val66Met genotype, gender, WTAR FSIQ, education
and included LEQ variables on serum BDNF concentration loge(pg/ml).
Model 1 BDNF in serum log(pg/ml) Model 2 BDNF in serum log(pg/ml)
Predictors Estimates 95% CI p Estimates 95% CI p
(lower, upper) (lower, upper)
(Intercept) 11.109 10.161, 12.058 <0.001 10.397 9.903, 10.892 <0.001
Age (years) −0.005 −0.012, 0.003 0.21 −0.008 −0.015,−0.001 0.032
BDNF Val 66 Met genotype: met+ 0.084 −0.006, 0.174 0.066 0.08 −0.009, 0.169 0.077
Gender: Male −0.098 −0.195,−0.002 0.046 −0.109 −0.203,−0.015 0.023
WTAR FSIQ −0.006 −0.014, 0.002 0.173
FTE Years of university 0.01 −0.024, 0.043 0.566
Study (THBP intervention)
LEQ young adulthood specific (education and training) 0.009 0.003, 0.015 0.004 0.007 0.001, 0.012 0.022
LEQ young adulthood general −0.001 −0.010, 0.008 0.902
LEQ midlife −0.008 −0.019, 0.003 0.147
Specific (occupation)
LEQ midlife general −0.007 −0.017, 0.003 0.188
LEQ midlife bonus (education and training) −0.006 −0.011,−0.001 0.029 −0.007 −0.012,−0.001 0.013
Observations 144 144
R2/R2 adjusted 0.188/0.127 0.146/0.115
Bold values indicate p-values were considered significant (p < .05). BDNF, brain-derived neurotrophic factor; CI, confidence interval; FTE, full-time equivalent; LEQ, lifetime experience
questionnaire; THBP, Tasmanian Healthy Brain Project; WTAR FSIQ, Weschler Test of Adult Reading Full-Scale Intelligence Quotient.
FIGURE 1 | Estimated marginal mean trends for (A) age stratified by gender, (B) lifetime of experiences questionnaire (LEQ) midlife education and LEQ young
adulthood education. Points are observed data, shaded regions represent 95% confidence intervals. Females had small, but significantly higher mean (log) serum
BDNF than males, and concentrations decreased with each year of age (in adults older than 58 years of age). Cross-sectional serum BDNF concentrations increased
with higher young adulthood education and training scores, but decreased with higher mid-life education and training scores on the LEQ.
levels of serum BDNF than both cognitively normal people and
people with more severe stage AD. Therefore, the relationship
between serum BDNF levels and dementia is not clear and may
be dependent on cognitive health and vary across normal and
pathological cognitive aging trajectories.
Lower BDNF levels in the periphery may represent several
scenarios, ranging from decreased production in the brain,
reduced neurogenesis, reduced activity-dependent plasticity, less
transport to the vasculature, greater uptake by neural cells
and/or greater efficiency in the use of this factor. We currently
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lack a specific neural correlate of cognitive reserve, but it
is a capacity that can be built through lifetime experience
and provides functional compensation for the accumulation
of pathology (Stern, 2002). Furthermore, as BDNF is released
following cognitive stimulation (Novkovic et al., 2015), it
may be that people with higher cognitive reserve find tasks
of daily living less cognitively demanding than people with
lower cognitive reserve, and thus release less BDNF into the
serum. In the current study of healthy adults, we observed
that higher levels of education in young adulthood and lower
levels of education in mid-life were both significantly associated
with an increase in serum BDNF. Although our results are
cross-sectional, this indicates the relationship between cognitive
stimulation and circulating pools of BDNF may vary throughout
the lifespan.
The current study did not find any significant difference in
serum BDNF levels between BDNF Met+ and Met- participants
but did find significantly lower BDNF levels in males compared
to female participants. Previous research has shown disparities in
BDNF serum levels between BDNF Met+ vs. Met- participants,
with increased levels shown in a study of 114 healthy
controls (Lang et al., 2009), decreased levels demonstrated
in 122 participants (66 healthy controls; 56 major depressive
disorder, Ozan et al., 2010) and no difference found in a
group of 198 participants [99 healthy controls; 99 amnestic
mild cognitive impairment (aMCI), Yu et al., 2008]. Given
strong gene × environment interactions in aging, the impact
of BDNF Met polymorphism on circulating serum BDNF may
vary throughout an individual’s life and be mediated through
other biopsychosocial factors that were outside the scope of
this study. Similarly, there has been a disparity in the effect
of gender on serum BDNF levels, with no difference between
the genders (Lang et al., 2009) as well as both higher (Shimada
et al., 2014) and lower (Ozan et al., 2010) levels in females
reported. Our results align closely with those reported by
Weinstein et al. (2014), where there was no effect of the
Val66Met BDNF polymorphism on serum BDNF levels and
that participants in the two lowest quintiles of serum BDNF
levels were significantly older, more likely to be males and have
an education of at least college degree or higher. Although
our study was unable to investigate hormonal pathways,
serum BDNF levels may be related to sex-specific hormones,
as BDNF levels are associated with estrogen, progesterone,
and testosterone levels and affected by menopausal changes
in estrogen and hormone replacement therapy (Begliuomini
et al., 2007; Chan and Ye, 2017). Furthermore, the rate
of sex hormone changes over aging differs between males
and females (Pluchino et al., 2013) and thus the age of
participants and sample sizes of studies may explain the differing
results reported.
We did not observe a significant relationship between
estimated premorbid intelligence or participation in the
university-level education intervention and serum BDNF levels.
This supports a previous study in healthy older adults between
the ages of 65 and 85 years which assessed acute changes in serum
BDNF levels following physical activity, mindfulness practice,
or cognitive training and found that only physical activity
caused a significant increase in serum BDNF levels (Håkansson
et al., 2017). Furthermore, a study of older adults with aMCI
demonstrated that there was no significant change in serum
BDNF levels following 12-weeks of either group- or home-based
cognitive interventions (Jeong et al., 2016). However, serum
BDNF levels did significantly correlate with improvements
in cognition following the group- and home-based cognitive
interventions (Jeong et al., 2016). As we did not include a
measure of physical activity in our study, we are unable to
determine any differences in activity across strata of engagement
with the university study intervention or mid-life education. We
speculate participants with lower levels of mid-life education
may potentially be in more physically demanding occupations,
thereby increasing their circulating levels of serum BDNF. It is a
substantial limitation that we were unable to measure changes
in serum BDNF levels pre- and post-intervention. Ongoing
data collection in the THBP will allow us to investigate the
relationship between activities that build cognitive reserve and
changes in serum BDNF levels over time. Participants who
undertook later-life university study displayed similar levels of
previous education and were a similar mean age to those who
did not, therefore we do not consider these results to be at
high risk of bias by non-random, self-selection. We acknowledge
the limitations in this study of a small sample size, which is
inherent to longitudinal studies of this length and the healthy
cohort bias, as participants of THBP display higher levels of
education compared to the general population. We were also
unable to adjust for other variables that may explain additional
variance in serum BDNF levels, such as physical activity, diet,
metabolic diseases, smoking and other substance use, social
engagement, and stress. A strength of the current study was that
the immunoassay used to assess serum BDNF levels is specific
for the mature form of the BDNF protein and does not detect
pro-BDNF, which is important because pro-BDNF and BDNF
have differing effects on the brain (Carlino et al., 2013; Polacchini
et al., 2015).
In conclusion, this study demonstrates for the first time, in
healthy older adults, that the period of life in which education
and training take place may moderate the association between
education and training and serum BDNF levels in later life.
The observed associations were opposed, independent and their
estimated effect sizes were similar, suggesting that education at
different stages of life may be associated with different cognitive
and neural demands. Education may build networks in young
adulthood, whilst preserving existing networks in mid-life. We
conclude that education is important at different stages of life
and should be accounted for as covariates when estimating
associations between age-related health predictors and serum
BDNF.
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